In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors.

In a series of lawsuits filed this year, Novartis has alleged that several rivals have infringed on patents for one or both of its commercial radioligand therapies Pluvicto and Lutathera.